PRINCETON, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter and full year of 2022 and issued guidance for 2023.
Fourth Quarter Highlights:
Full Year Highlights:
“We are pleased with our strong finish to 2022, and the significant progress we made across our strategic initiatives throughout the year” said William F. Feehery, chief executive officer. “The prospects for Certara remain very bright and we are well positioned to deliver on our 2023 financial and strategic objectives. We enter 2023 encouraged by the pace of market adoption and expanding awareness of Certara’s biosimulation platform worldwide.”
Fourth Quarter 2022 Results
“We enter 2023 following a strong second half of 2022 and are well positioned to execute on our full year 2023 revenue and profitability guidance given strong business momentum and bookings growth on a trailing twelve-month basis. We are focused on our long-term growth objectives and finished 2022 with a strong balance sheet,” said Andrew Schemick, chief financial officer.
Total revenue for the fourth quarter of 2022 was $86.6 million, representing growth of 15% over the fourth quarter of 2021. The overall increase in revenue was primarily due to growth in our technology-driven services and software product offerings from strong renewal rates, client expansion, and new customers as well as business acquisitions. The increase was partially offset by the negative impact on our revenues from fluctuations foreign currency exchange rates.
On a constant currency basis, total revenue for the fourth quarter of 2022 was $89.2 million, representing growth of 18% over the fourth quarter of 2021. Please see note (1) in the section A Note on Non-GAAP Financial Measures below for more information on constant currency revenue.
Total cost of revenue for the fourth quarter of 2022 was $31.8 million, an increase of $2.5 million from $29.3 million in the fourth quarter of 2021, primarily due to a $3.6 million increase in employee-related costs resulting from billable headcount growth, a $0.3 million increase in travel expenses, and a $0.2 million increase related to cost of licenses, partially offset by a $0.8 million decrease in stock-based compensation cost, and a $0.8 million decrease in professional and consulting cost.
Total operating expenses for the fourth quarter of 2022 were $43.5 million, increased by $0.9 million from $42.6 million in the fourth quarter of 2021, primarily due to a $3.3 million increase in employee-related costs, a $0.4 million increase in professional and consulting cost, a $0.5 million increase in marketing and travel expenses, partially offset by a $1.3 million decrease in stock-based compensation cost, a $0.8 million decrease in business acquisition costs, a $0.6 million increase in capitalized cost in research and development, and a $0.6 million decrease in public offering cost.
Net income for the fourth quarter of 2022 was $9.2 million, compared to a net loss of $9.7 million in the fourth quarter of 2021. The $18.9 million increase in net income was primarily due to a $11.3 million increase in total revenue, a $15.0 million decrease in tax expense, a $0.9 million increase in interest income, partially offset by a $2.5 million increase in cost of revenue, a $2.2 million increase in interest expense, a $2.5 million increase in currency loss, and a $0.9 million increase in operating expense.
Diluted earnings per share for the fourth quarter 2022 was $0.06, as compared to $(0.06) in the fourth quarter of 2021.
Adjusted EBITDA for the fourth quarter of 2022 was $31.9 million compared to $28.2 million for the fourth quarter of 2021, representing 13% growth. See note (2) in the section A Note on Non-GAAP Financial Measures below for more information on adjusted EBITDA.
Adjusted net income for the fourth quarter of 2022 was $25.2 million compared to $9.8 million for the fourth quarter of 2021. Adjusted diluted earnings per share for the fourth quarter 2022 was $0.16 compared to $0.06 for the fourth quarter of 2021. See note (3) in the section A Note on Non-GAAP Financial Measures below for more information on adjusted net income and adjusted diluted earnings per share.
| Three Months Ended December 31, | Years Ended December 31, | |||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||
| Key Financials (in millions, except per share data) | ||||||||||||||
| Revenue | $ | 86.6 | $ | 75.3 | $ | 335.6 | $ | 286.1 | ||||||
| Net income (loss) | $ | 9.2 | $ | (9.7 | ) | $ | 14.7 | $ | (13.3 | ) | ||||
| Diluted earnings per share | $ | 0.06 | $ | (0.06 | ) | $ | 0.09 | $ | (0.09 | ) | ||||
| Adjusted EBITDA | $ | 31.9 | $ | 28.2 | $ | 120.2 | $ | 103.7 | ||||||
| Adjusted net income | $ | 25.2 | $ | 9.8 | $ | 73.4 | $ | 53.2 | ||||||
| Adjusted diluted earnings per share | $ | 0.16 | $ | 0.06 | $ | 0.46 | $ | 0.34 | ||||||
| Cash and cash equivalents | $ | 236.6 | $ | 185.8 | ||||||||||
2023 Financial Outlook
Certara expects the following:
Full year 2023 revenue to be in the range of $370 million to $385 million.
Full year 2023 adjusted EBITDA to be in the range of $131 million to $137 million.
Full year adjusted diluted earnings per share to be in the range of $0.50 - $0.55.
Fully diluted shares to be in the range of 159 million to 162 million.
Webcast and Conference Call Details
Certara will host a conference call today, March 1, 2022, at 5:00 p.m. ET to discuss its fourth quarter 2022 financial results. Investors interested in listening to the conference call are required to register online in advance of the call. A live and archived webcast of the event will be available on the “Investors” section of the Certara website at https://ir.certara.com/.
About Certara
Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.
Please visit our website at www.certara.com. We intend to use our website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD.
Such disclosures will be included in the Investor Relations section of our website at https://ir.certara.com. Accordingly, investors should monitor such portion of our website, in addition to following our press releases, Securities and Exchange Commission filings and public conference calls and webcasts.
Forward-Looking Statements
This press release contains certain statements that constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, with respect to the Company’s future business and financial performance, revenue, margin, and bookings. These statements typically contain words such as “believe,” “may,” “potential,” “will,” “plan,” “could,” “estimate,” “expects” and “anticipates” or the negative of these words or other similar terms or expressions. Any statement in this press release that is not a statement of historical fact is a forward-looking statement and involves significant risks and uncertainties. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot provide any assurance that these expectations will prove to be correct. You should not rely upon forward-looking statements as predictions of future events and actual results, events, or circumstances. Actual results may differ materially from those described in the forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including the Company’s ability to compete within its market; any deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery; changes or delays in relevant government regulation; increasing competition, regulation and other cost pressures within the pharmaceutical and biotechnology industries; economic conditions, including inflation, recession and currency exchange fluctuation; trends in research and development (R&D) spending; delays or cancellations in projects due to supply chain interruptions or disruptions or delays to pipeline development and clinical trials experienced by our customers due to COVID-19 or other external factors; consolidation within the biopharmaceutical industry; reduction in the use of the Company’s products by academic institutions; pricing pressures; the Company’s ability to successfully enter new markets, increase its customer base and expand its relationships with existing customers; the impact of acquisitions and our ability to successfully integrate such acquisitions; the occurrence of natural disasters and epidemic diseases, such as the recent COVID-19 pandemic; the occurrence of global conflicts, such as the conflict between Russian and Ukraine; any delays or defects in the release of new or enhanced software or other biosimulation tools; failure of our existing customers to renew their software licenses or any delays or terminations of contracts or reductions in scope of work by its existing customers; our ability to accurately estimate costs associated with its fixed-fee contracts; our ability to retain key personnel or recruit additional qualified personnel; lower utilization rates by our employees as a result of natural disasters and epidemic diseases; risks related to our contracts with government customers; our ability to sustain recent growth rates; our ability to successfully operate a global business; our ability to comply with applicable laws and regulations; risks related to litigation; the adequacy of its insurance coverage and ability to obtain adequate insurance coverage in the future; our ability to perform in accordance with contractual requirements, regulatory standards and ethical considerations; the loss of more than one of our major customers; future capital needs; the ability of our bookings to accurately predict future revenue and our ability to realize revenue on bookings; disruptions in the operations of the third-party providers who host our software solutions or any limitations on their capacity; our ability to reliably meet data storage and management requirements, or the experience of any failures or interruptions in the delivery of our services over the internet; our ability to comply with the terms of any licenses governing use of third-party open source software; any breach of its security measures or unauthorized access to customer data; our ability to adequately enforce or defend ownership and use of our intellectual property and other proprietary rights; any allegations of infringement, misappropriation or violations of a third party’s intellectual property rights; our ability to meet obligations under indebtedness and have sufficient capital to operate our business; any limitations on our ability to pursue business strategies due to restrictions under our current or future indebtedness; any impairment of goodwill or other intangible assets; our ability to use our net operating losses and R&D tax credit carryforwards; the accuracy of management’s estimates and judgments relating to critical accounting policies and changes in financial reporting standards or interpretations; any inability to design, implement, and maintain effective internal controls or inability to remediate any internal controls deemed ineffective; the costs and management time associated with operating as a publicly traded company; and the other factors detailed under the captions “Risk Factors” and “Special Note Regarding Forward-Looking Statements” and elsewhere in our Securities and Exchange Commission (“SEC”) filings, and reports, including the Form 10-K filed by the Company with the Securities and Exchange Commission on March 1, 2023, and subsequent reports filed with the SEC. Any forward-looking statements speak only as of the date of this release and, except to the extent required by applicable securities laws, we expressly disclaim any obligation to update or revise any of them to reflect actual results, any changes in expectations or any change in events. Factors that may materially affect our results and those risks listed in filings with the SEC.
A Note on Non-GAAP Financial Measures
This press release contains “non-GAAP measures” that are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles (“GAAP”). Specifically, the Company makes use of the non-GAAP financial measures adjusted EBITDA, adjusted net income (loss), adjusted diluted earnings per share, and constant currency (“CC”) revenue, which are not recognized terms under GAAP. These measures should not be considered as alternatives to net income (loss) or GAAP diluted earnings per share or revenue as measures of financial performance or any other performance measure derived in accordance with GAAP and should not be considered a measure of discretionary cash available to the Company to invest in the growth of its business. The presentation of these measures has limitations as an analytical tool and should not be considered in isolation, or as a substitute for the Company’s results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.
You should refer to the footnotes below as well as the “Non-GAAP Financial Measures” section in this press release below for a further explanation of these measures and reconciliations of these non-GAAP measures in specific periods to their most directly comparable financial measure calculated and presented in accordance with GAAP for those periods.
Management uses various financial metrics, including total revenues, income (loss) from operations, net income (loss), and certain non-GAAP measures, including those discussed above, to measure and assess the performance of the Company’s business, to evaluate the effectiveness of its business strategies, to make budgeting decisions, to make certain compensation decisions, and to compare the Company’s performance against that of other peer companies using similar measures. In addition, management believes these metrics provide useful measures for period-to-period comparisons of the Company’s business, as they remove the effect of certain non-cash expenses and other items not indicative of its ongoing operating performance.
Management believes that adjusted EBITDA, adjusted net income (loss), adjusted diluted earnings per share, and CC revenue are helpful to investors, analysts, and other interested parties because they can assist in providing a more consistent and comparable overview of our operations across our historical periods. In addition, each of these measures is frequently used by analysts, investors, and other interested parties to evaluate and assess performance. Furthermore, our business has operations outside the United States that are conducted in local currencies. As a result, the comparability of the financial results reported in U.S. dollars is affected by changes in foreign currency exchange rates. We adjust revenues for constant currency to provide a framework for assessing how our business performed excluding the effect of foreign currency rate fluctuations and we believe it is helpful for investors to present operating results on a comparable basis period over period to evaluate its underlying performance.
Please note that the Company has not reconciled the adjusted EBITDA or adjusted diluted earnings per share forward-looking guidance included in this press release to the most directly comparable GAAP measures because this cannot be done without unreasonable effort due to the variability and low visibility with respect to costs related to acquisitions, financings, and employee stock compensation programs, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.
In evaluating adjusted EBITDA, adjusted net income, and adjusted diluted earnings per share, you should be aware that in the future the Company may incur expenses similar to those eliminated in this presentation and this presentation should not be construed as an inference that future results will be unaffected by unusual items.
Contacts:
Investor Relations Contact:
David Deuchler
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Daniel Yunger
Kekst CNC
This email address is being protected from spambots. You need JavaScript enabled to view it.
CERTARA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| THREE MONTHS ENDED | YEARS ENDED | |||||||||||||||
| DECEMBER 31, | DECEMBER 31, | |||||||||||||||
| (IN THOUSANDS, EXCEPT PER SHARE AND SHARE DATA) | 2022 | 2021 | 2022 | 2021 | ||||||||||||
| Revenues | $ | 86,633 | $ | 75,346 | $ | 335,644 | $ | 286,104 | ||||||||
| Cost of revenues | 31,782 | 29,289 | 132,577 | 111,616 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Sales and marketing | 7,800 | 6,718 | 27,408 | 20,141 | ||||||||||||
| Research and development | 6,598 | 6,517 | 28,205 | 20,379 | ||||||||||||
| General and administrative | 18,329 | 18,744 | 71,773 | 79,539 | ||||||||||||
| Intangible asset amortization | 10,334 | 10,188 | 41,429 | 38,715 | ||||||||||||
| Depreciation and amortization expense | 410 | 448 | 1,731 | 2,135 | ||||||||||||
| Total operating expenses | 43,471 | 42,615 | 170,546 | 160,909 | ||||||||||||
| Income (loss) from operations | 11,380 | 3,442 | 32,521 | 13,579 | ||||||||||||
| Other expenses: | ||||||||||||||||
| Interest expense | (5,445 | ) | (3,288 | ) | (17,773 | ) | (16,837 | ) | ||||||||
| Net other income (expense) | (2,210 | ) | (311 | ) | 4,007 | (117 | ) | |||||||||
| Total other expenses | (7,655 | ) | (3,599 | ) | (13,766 | ) | (16,954 | ) | ||||||||
| Income (loss) before income taxes | 3,725 | (157 | ) | 18,755 | (3,375 | ) | ||||||||||
| Provision for (benefit from) income taxes | (5,449 | ) | 9,542 | 4,024 | 9,891 | |||||||||||
| Net income (loss) | $ | 9,174 | $ | (9,699 | ) | $ | 14,731 | $ | (13,266 | ) | ||||||
| Net income (loss) per share attributable to common stockholders: | ||||||||||||||||
| Basic | $ | 0.06 | $ | (0.06 | ) | $ | 0.09 | $ | (0.09 | ) | ||||||
| Diluted | $ | 0.06 | $ | (0.06 | ) | $ | 0.09 | $ | (0.09 | ) | ||||||
| Weighted average common shares outstanding: | ||||||||||||||||
| Basic | 157,927,161 | 155,624,454 | 156,876,942 | 149,842,668 | ||||||||||||
| Diluted | 159,241,217 | 155,624,454 | 159,354,394 | 149,842,668 | ||||||||||||
CERTARA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
| DECEMBER 31, | DECEMBER 31, | |||||||
| (IN THOUSANDS, EXCEPT PER SHARE AND SHARE DATA) | 2022 | 2021 | ||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 236,586 | $ | 185,797 | ||||
| Accounts receivable, net of allowances for credit losses of $1,250 and $262, respectively | 82,584 | 69,555 | ||||||
| Restricted cash | 3,102 | 827 | ||||||
| Prepaid expenses and other current assets | 19,980 | 18,548 | ||||||
| Total current assets | 342,252 | 274,727 | ||||||
| Other assets: | ||||||||
| Property and equipment, net | 2,400 | 2,935 | ||||||
| Operating lease right-of-use assets | 14,427 | 12,634 | ||||||
| Goodwill | 717,743 | 703,371 | ||||||
| Intangible assets, net of $217,705 and $169,329, respectively | 486,782 | 511,823 | ||||||
| Deferred income taxes | 3,703 | 4,073 | ||||||
| Other long-term assets | 5,615 | 2,167 | ||||||
| Total assets | $ | 1,572,922 | $ | 1,511,730 | ||||
| Liabilities and stockholder’s equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 7,533 | $ | 7,458 | ||||
| Accrued expenses | 35,403 | 29,830 | ||||||
| Current portion of deferred revenue | 52,209 | 45,496 | ||||||
| Current portion of long-term debt | 3,020 | 3,020 | ||||||
| Current operating lease liabilities | 4,968 | 5,040 | ||||||
| Other current liabilities | 25 | 1,381 | ||||||
| Total current liabilities | 103,158 | 92,225 | ||||||
| Long-term liabilities: | ||||||||
| Deferred revenue, net of current portion | 2,815 | 1,531 | ||||||
| Deferred income taxes | 65,046 | 76,098 | ||||||
| Operating lease liabilities, net of current portion | 10,133 | 8,256 | ||||||
| Long-term debt, net of current portion and debt discount | 289,988 | 291,746 | ||||||
| Other long-term liabilities | 22,121 | 25 | ||||||
| Total liabilities | 493,261 | 469,881 | ||||||
| Commitments and contingencies | ||||||||
| Stockholder’s equity | ||||||||
| Preferred shares, $0.01 par value, 50,000,000 and no shares authorized as of December 31, 2022 and 2021, respectively, no shares issued and outstanding as of December 31, 2022 and 2021, respectively | — | — | ||||||
| Common shares, $0.01 par value, 600,000,000 shares authorized, 159,525,943 and 159,658,948 shares outstanding as of December 31, 2022 and 2021, respectively | 1,596 | 1,596 | ||||||
| Additional paid-in capital | 1,150,168 | 1,119,821 | ||||||
| Accumulated deficit | (60,873 | ) | (75,604 | ) | ||||
| Accumulated other comprehensive loss | (8,230 | ) | (3,926 | ) | ||||
| Treasury stock at cost, 150,207 and 1,100 shares at December 31, 2022 and 2021, respectively | (3,000 | ) | (38 | ) | ||||
| Total stockholder’s equity | 1,079,661 | 1,041,849 | ||||||
| Total liabilities and stockholder’s equity | $ | 1,572,922 | $ | 1,511,730 | ||||
CERTARA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| YEARS ENDED DECEMBER 31 | ||||||||
| (IN THOUSANDS) | 2022 | 2021 | ||||||
| Cash flows from operating activities: | ||||||||
| Net income (loss) | $ | 14,731 | $ | (13,266 | ) | |||
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||||||||
| Depreciation and amortization of property and equipment | 1,731 | 2,135 | ||||||
| Amortization of intangible assets | 50,739 | 42,980 | ||||||
| Amortization of debt issuance costs | 1,540 | 1,531 | ||||||
| (Recovery of) provision for credit losses | 1,072 | 130 | ||||||
| Loss on retirement of assets | 169 | 351 | ||||||
| Equity-based compensation expense | 30,345 | 29,483 | ||||||
| Unrealized loss on derivative | — | 1,144 | ||||||
| Deferred income taxes | (11,511 | ) | (1,184 | ) | ||||
| Changes in assets and liabilities, net of acquisitions: | ||||||||
| Accounts receivable | (15,009 | ) | (10,066 | ) | ||||
| Prepaid and other assets | 126 | 585 | ||||||
| Accounts payable and accrued expenses | 5,289 | 1,421 | ||||||
| Deferred revenue | 9,530 | 5,435 | ||||||
| Change in other liabilities | 3,791 | (291 | ) | |||||
| Net cash provided by operating activities | 92,543 | 60,388 | ||||||
| Cash flows from investing activities: | ||||||||
| Capital expenditures | (1,430 | ) | (1,143 | ) | ||||
| Capitalized software development costs | (11,099 | ) | (7,759 | ) | ||||
| Business acquisitions, net of cash acquired | (15,308 | ) | (261,020 | ) | ||||
| Net cash used in investing activities | (27,837 | ) | (269,922 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from issuance of common stock, net of underwriters' discounts and commissions | — | 133,351 | ||||||
| Proceeds from borrowings on long-term debt | — | 89 | ||||||
| Payments on long-term debt and finance lease obligations | (3,313 | ) | (3,973 | ) | ||||
| Payments on financing component of interest rate swap | (1,088 | ) | (1,095 | ) | ||||
| Payment of deferred offering costs | — | (1,767 | ) | |||||
| Payment of debt issuance costs | — | (2,942 | ) | |||||
| Payment of taxes on shares and units withheld for employee taxes | (2,962 | ) | (272 | ) | ||||
| Net cash provided by (used in) financing activities | (7,363 | ) | 123,391 | |||||
| Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash | (4,279 | ) | (2,942 | ) | ||||
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 53,064 | (89,085 | ) | |||||
| Cash, cash equivalents, and restricted cash, at beginning of year | 186,624 | 273,291 | ||||||
| Cash, cash equivalents, and restricted cash, at end of year | $ | 239,688 | $ | 184,206 | ||||
NON-GAAP FINANCIAL MEASURES
The following table reconciles net income (loss) to adjusted EBITDA:
| THREE MONTHS ENDED DECEMBER 31 | TWELVE MONTHS ENDED DECEMBER 31 | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| (in thousands) | ||||||||||||||||
| Net income (loss) | $ | 9,174 | $ | (9,699 | ) | $ | 14,731 | $ | (13,266 | ) | ||||||
| Interest expense(a) | 5,445 | 3,288 | 17,773 | 16,837 | ||||||||||||
| Interest income(a) | (947 | ) | (16 | ) | (1,294 | ) | (271 | ) | ||||||||
| (Benefit from) provision for income taxes(a) | (5,449 | ) | 9,542 | 4,024 | 9,891 | |||||||||||
| Depreciation and amortization expense(a) | 410 | 448 | 1,731 | 2,135 | ||||||||||||
| Intangible asset amortization(a) | 12,732 | 12,544 | 50,739 | 42,980 | ||||||||||||
| Currency (gain) loss(a) | 2,473 | 14 | (3,166 | ) | (175 | ) | ||||||||||
| Equity-based compensation expense(b) | 6,527 | 8,637 | 30,345 | 29,483 | ||||||||||||
| Acquisition-related expense(d) | 902 | 1,528 | 2,233 | 11,241 | ||||||||||||
| Integration expense(e) | — | 31 | — | 31 | ||||||||||||
| Transaction related expenses(f) | 412 | 978 | 1,136 | 2,754 | ||||||||||||
| Severance expense(g) | (69 | ) | 60 | 653 | 60 | |||||||||||
| Loss on disposal of fixed assets(h) | 113 | 47 | 169 | 351 | ||||||||||||
| Executive recruiting expense(i) | 139 | 320 | 139 | 733 | ||||||||||||
| First-year Sarbanes-Oxley and ASC 842 implementation costs(j) | — | 460 | 961 | 929 | ||||||||||||
| Adjusted EBITDA | $ | 31,862 | $ | 28,182 | $ | 120,174 | $ | 103,713 | ||||||||
The following table reconciles net income (loss) to adjusted net income:
| THREE MONTHS ENDED DECEMBER 31 | TWELVE MONTHS ENDED DECEMBER 31 | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| (in thousands) | ||||||||||||||||
| Net income (loss) | $ | 9,174 | $ | (9,699 | ) | $ | 14,731 | $ | (13,266 | ) | ||||||
| Currency (gain) loss(a) | 2,473 | 14 | (3,166 | ) | (175 | ) | ||||||||||
| Equity-based compensation expense(b) | 6,527 | 8,637 | 30,345 | 29,483 | ||||||||||||
| Amortization of acquisition-related intangible assets(c) | 10,922 | 10,941 | 43,822 | 36,413 | ||||||||||||
| Acquisition-related expense(d) | 902 | 1,528 | 2,233 | 11,241 | ||||||||||||
| Integration expense(e) | — | 31 | — | 31 | ||||||||||||
| Transaction related expenses(f) | 412 | 978 | 1,136 | 2,754 | ||||||||||||
| Severance expense(g) | (69 | ) | 60 | 653 | 60 | |||||||||||
| Loss on disposal of fixed assets(h) | 113 | 47 | 169 | 351 | ||||||||||||
| Executive recruiting expense(i) | 139 | 320 | 139 | 733 | ||||||||||||
| First-year Sarbanes-Oxley and ASC 842 implementation costs(j) | — | 460 | 961 | 929 | ||||||||||||
| Income tax expense impact of adjustments(k) | (5,397 | ) | (3,549 | ) | (17,633 | ) | (15,344 | ) | ||||||||
| Adjusted net income | $ | 25,196 | $ | 9,768 | $ | 73,390 | $ | 53,210 | ||||||||
The following table reconciles diluted earnings per share to adjusted diluted earnings per share:
| THREE MONTHS ENDED DECEMBER 31 | TWELVE MONTHS ENDED DECEMBER 31 | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| (in thousands except share and per share data) | ||||||||||||||||
| Diluted earnings per share(a) | $ | 0.06 | $ | (0.06 | ) | $ | 0.09 | $ | (0.09 | ) | ||||||
| Currency (gain) loss(a) | 0.02 | — | (0.02 | ) | — | |||||||||||
| Equity-based compensation expense(b) | 0.04 | 0.05 | 0.19 | 0.19 | ||||||||||||
| Amortization of acquisition-related intangible assets(c) | 0.06 | 0.07 | 0.28 | 0.24 | ||||||||||||
| Acquisition-related expense(d) | 0.01 | 0.01 | 0.01 | 0.07 | ||||||||||||
| Integration expense(e) | — | — | — | — | ||||||||||||
| Transaction related expenses(f) | — | 0.01 | 0.01 | 0.02 | ||||||||||||
| Severance expense(g) | — | — | — | — | ||||||||||||
| Loss on disposal of fixed assets(h) | — | — | — | — | ||||||||||||
| Executive recruiting expense(i) | — | — | — | — | ||||||||||||
| First-year Sarbanes-Oxley and ASC 842 implementation costs(j) | — | — | 0.01 | 0.01 | ||||||||||||
| Income tax expense impact of adjustments(k) | (0.03 | ) | (0.02 | ) | (0.11 | ) | (0.10 | ) | ||||||||
| Adjusted diluted earnings per share | $ | 0.16 | $ | 0.06 | $ | 0.46 | $ | 0.34 | ||||||||
| Basic weighted average common shares outstanding | 157,927,161 | 155,624,454 | 156,876,942 | 149,842,668 | ||||||||||||
| Effect of potentially dilutive shares outstanding (l) | 1,314,056 | 3,857,176 | 2,477,452 | 4,401,021 | ||||||||||||
| Adjusted diluted weighted average common shares outstanding | 159,241,217 | 159,481,630 | 159,354,394 | 154,243,689 | ||||||||||||
The following tables reconcile revenues to the revenues adjusted for constant currency:
| THREE MONTHS ENDED DECEMBER 31, | CHANGE | ||||||||||||||||||||||
| 2022 | 2022 | 2021 | $ | % | $ | % | |||||||||||||||||
| Actual | CC | Actual | Actual | Actual | CC Impact | Adjust for CC | |||||||||||||||||
| (GAAP) | (non-GAAP) | (GAAP) | (GAAP) | (GAAP) | (non-GAAP) | (non-GAAP) | |||||||||||||||||
| (in thousands) | |||||||||||||||||||||||
| Revenue | |||||||||||||||||||||||
| Software | $ | 29,156 | $ | 30,385 | $ | 25,541 | $ | 3,615 | 14 | % | $ | 1,229 | 19 | % | |||||||||
| Services | 57,477 | 58,805 | 49,805 | 7,672 | 15 | % | 1,328 | 18 | % | ||||||||||||||
| Total Revenue | $ | 86,633 | $ | 89,190 | $ | 75,346 | $ | 11,287 | 15 | % | $ | 2,557 | 18 | % | |||||||||
| TWELVE MONTHS ENDED DECEMBER 31, | CHANGE | ||||||||||||||||||||||
| 2022 | 2022 | 2021 | $ | % | $ | % | |||||||||||||||||
| Actual | CC | Actual | Actual | Actual | CC Impact | Adjust for CC | |||||||||||||||||
| (GAAP) | (non-GAAP) | (GAAP) | (GAAP) | (GAAP) | (non-GAAP) | (non-GAAP) | |||||||||||||||||
| (in thousands) | |||||||||||||||||||||||
| Revenue | |||||||||||||||||||||||
| Software | $ | 115,466 | $ | 119,391 | $ | 86,825 | $ | 28,641 | 33 | % | $ | 3,925 | 38 | % | |||||||||
| Services | 220,178 | 224,492 | 199,279 | 20,899 | 10 | % | 4,314 | 13 | % | ||||||||||||||
| Total Revenue | $ | 335,644 | $ | 343,883 | $ | 286,104 | $ | 49,540 | 17 | % | $ | 8,239 | 20 | % | |||||||||
(a) Represents amounts as determined under GAAP.
(b) Represents expense related to equity-based compensation. Equity-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy.
(c) Represents amortization costs associated with acquired intangible assets in connection with business acquisitions.
(d) Represents costs associated with acquisitions and any retention bonuses pursuant to the acquisitions.
(e) Represents integration costs related to post - acquisition integration activities.
(f) Represents costs associated with our public offerings that are not capitalized.
(g) Represents charges for severance provided to former executives.
(h) Represents the gain/loss related to disposal of fixed assets.
(i) Represents recruiting and relocation expenses related to hiring senior executives.
(j) Represents the first-year Sarbanes-Oxley costs for accounting and consulting fees related to the Company's preparation to comply with Section 404 of the Sarbanes-Oxley Act, as well as implementation cost of adopting ASC 842.
(k) Represents the income tax effect of the non-GAAP adjustments calculated using the applicable statutory rate by jurisdiction.
(l) Represents dilutive shares or potentially dilutive shares that were excluded from the Company's GAAP diluted weighted average common shares outstanding because the Company had a reported net loss and therefore including these shares would have been anti-dilutive.
| Last Trade: | US$10.71 |
| Daily Change: | 0.16 1.52 |
| Daily Volume: | 2,102,663 |
| Market Cap: | US$1.720B |
December 02, 2024 November 06, 2024 September 18, 2024 August 15, 2024 August 06, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
